PTD802 / Pheno Therapeutics, UCB - LARVOL DELTA

GPR17 - orphan G protein-coupled receptor with therapeutic potential. (PubMed, Trends Pharmacol Sci) - "Only recently, potent and selective tool compounds for GPR17 have become available, and patents on antagonists have surged, leading to the first clinical candidate, the GPR17 antagonist PTD802, which is to be developed for MS therapy...The newly determined cryo-electron microscopy (cryo-EM) structure of GPR17 is expected to facilitate future structure-based drug design efforts. This review presents and discusses these latest developments, providing a timely and comprehensive overview to guide future research in the field."

Journal • Review • CNS Disorders • Multiple Sclerosis

Pheno Therapeutics Granted Clinical Trial Authorisation for Lead Multiple Sclerosis Therapeutic Candidate PTD802 (Businesswire) - "Pheno Therapeutics Limited...announced today it has received clinical trial authorisation (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802."

New trial • Multiple Sclerosis